VERONICA: Randomized Phase II Study of Fulvestrant and Venetoclax in ER-Positive Metastatic Breast Cancer Post-CDK4/6 Inhibitors - Efficacy, Safety, and Biomarker Results.
Geoffrey J LindemanTharu M FernandoRebecca BowenKatarzyna J JerzakXinni SongThomas DeckerFrances BoyleSteven McCuneAnne C ArmstrongCatherine ShannonGianfilippo BertelliChing-Wei ChangRupal DesaiKushagra GuptaTimothy R WilsonAulde FlechaisAditya BardiaPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)
Our findings do not indicate clinical utility for venetoclax plus fulvestrant in endocrine therapy-resistant, CDK4/6 inhibitor-refractory metastatic breast tumors, but suggest possible increased dependence on BCLXL in this setting.
Keyphrases
- metastatic breast cancer
- phase ii study
- open label
- placebo controlled
- cell cycle
- chronic lymphocytic leukemia
- double blind
- phase iii
- phase ii
- locally advanced
- squamous cell carcinoma
- small cell lung cancer
- clinical trial
- study protocol
- cell proliferation
- estrogen receptor
- endoplasmic reticulum
- breast cancer cells
- randomized controlled trial
- radiation therapy
- stem cells
- mesenchymal stem cells
- rectal cancer
- replacement therapy